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A B S T R A C T   
Background and aims: Pseudoxanthoma elasticum (PXE) is caused by variants in the ABCC6 gene. It results in 
calcification in the skin, peripheral arteries and the eyes, but has considerable phenotypic variability. We 
investigated the association between the ABCC6 genotype and calcification and clinical phenotypes in these 
different organs. 
Methods: ABCC6 sequencing was performed in 289 PXE patients. Genotypes were grouped as two truncating, 
mixed, or two non-truncating variants. Arterial calcification mass was quantified on whole body, low dose CT 
scans; and peripheral arterial disease was measured with the ankle brachial index after treadmill test. The 
presence of pseudoxanthoma in the skin was systematically scored. Ophthalmological phenotypes were the 
length of angioid streaks as a measure of Bruchs membrane calcification, the presence of choroidal neo-
vascularizations, severity of macular atrophy and visual acuity. Regression models were built to test the age and 
sex adjusted genotype-phenotype association. 
Results: 158 patients (median age 51 years) had two truncating variants, 96 (median age 54 years) a mixed 
genotype, 18 (median age 47 years) had two non-truncating variants. The mixed genotype was associated with 
lower peripheral (β: 0.39, 95%CI:-0.62;-0.17) and total (β: 0.28, 95%CI:-0.47;-0.10) arterial calcification mass 
scores, and lower prevalence of choroidal neovascularizations (OR: 0.41 95%CI:0.20; 0.83) compared to two 
truncating variants. No association with pseudoxanthomas was found. 
Conclusions: PXE patients with a mixed genotype have less severe arterial and ophthalmological phenotypes than 
patients with two truncating variants in the ABCC6 gene. Research into environmental and genetic modifiers 
might provide further insights into the unexplained phenotypic variability.   
1. Introduction 
Pseudoxanthoma elasticum (PXE, OMIM 264800) is a rare autosomal 
recessive disorder characterized by the fragmentation and calcification 
of the elastic fibers of the skin, the peripheral arteries and Bruch’s 
membrane in the eyes [1]. In the skin, this results in pseudoxanthomas 
and severe skin loosening due to reduced elasticity [1]. In the 
vasculature, it results in peripheral arterial disease (PAD), but gastro-
intestinal bleeding and microvascular brain damage have also been re-
ported [1–3]. Calcification of Bruch’s membrane in the retina results in 
peau d’orange and angioid streaks. The latter are small fractures in 
Bruch’s membrane, which allow for the ingrowth of choroidal neo-
vascularizations with subsequent exudation, subretinal hemorrhage and 
scarring. Together with macular atrophy, this causes a high risk of visual 
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impairment in PXE [4]. 
PXE is caused by pathogenic variants in the ABCC6 gene, although 
overlapping phenotypes due to variants in the ENPP1 and GGCX genes 
have been reported [5]. ABCC6 encodes the ABCC6 transporter and is 
mainly expressed in the liver and kidneys [6]. The precise function of 
ABCC6 and its substrate is not yet fully understood. Low-grade inflam-
mation [7], elastin degradation [8], and the primary deficiency in 
calcification inhibitors might all underlie the systemic calcification seen 
in PXE [6]. It has been shown, however, that PXE results in low systemic 
levels of inorganic pyrophosphate (PPi). PPi is an important inhibitor of 
calcification and the low levels seen in PXE play a role in the increased 
multi-organ calcification [6,9]. 
The phenotype of PXE is highly variable between patients and even 
within families with the same causative variants [10]. Several studies 
investigated the association between the different genotypes and the 
clinical phenotypes to better predict the course of disease in individual 
patients [11–15]. These studies are complicated by the high number of 
different ABCC6 variants since several of the more than 300 variants 
that cause PXE are unique for different families [11,16]. In addition, due 
to the rarity of the disease, most studies are hindered by low patient 
numbers to reach adequate statistical power. One study showed that 
patients with two loss-of-function variants have an increased risk of 
developing subretinal hemorrhage or scarring and severe claudication, 
compared with patients with one or two non-truncating variants [11], 
but most studies could not find a genotype-phenotype correlation [12, 
13,15]. Most studies used (a modified version of) the Phenodex classi-
fication, which is a composite score of clinical outcomes in organs 
affected by PXE [12]. Since ectopic calcification underlies these clinical 
outcomes, measures of ectopic calcification could serve as an interme-
diate endpoint for clinical outcomes. 
To gain better insight into the etiology of PXE and the role of calci-
fication in different organs, we studied the genotypes, calcification 
measures and clinical phenotypes in the skin, arteries and the eyes in a 
large cohort of PXE patients. Furthermore, the association between the 
genotypes and these different phenotypes in PXE were investigated. 
2. Patients and methods 
2.1. Participants 
PXE patients were recruited from the Dutch National Expertise 
Center for PXE in the University Medical Center Utrecht, the 
Netherlands. Based on an estimated prevalence of 1:25,000 to 1:50,000 
[14,17,18], we assume that 40–90% of the PXE patients in the 
Netherlands have been seen in our hospital. All patients had a clinical 
diagnosis of PXE based on the criteria of Plomp et al. (2010) [1]. In short, 
patients had to present with two of the three following criteria: skin 
involvement (pseudoxanthomas), eye involvement (peau d’orange 
and/or angioid streaks), or genetic confirmation (biallelic variants in the 
ABCC6 gene or a first-degree relative with PXE). For this study, clinical 
and molecular data (genetics, CT scans, ankle-brachial index after 
treadmill tests, skin photography, ophthalmological examination and 
imaging) was used. This cross-sectional study was approved by the 
medical ethical review board of the University Medical Center Utrecht 
(IRB# 18-767, 15-446, 19-257). Participants gave written informed 
consent for the use of their medical files for research purposes. 
2.2. Genotyping 
Genomic DNA was isolated from whole blood. Specific primers were 
used to avoid the amplification of ABCC6 pseudogenes ψ1 and ψ2 [19]. 
All ABCC6 exons and the flanking intron sequences were analyzed as 
part of the genetic screening for regular clinical care. Sanger sequencing 
was performed to identify single nucleotide polymorphisms (SNPs) and 
small deletions and insertions, and multiplex ligation-dependent probe 
amplification (MLPA) was performed to screen for larger deletions in the 
ABCC6 gene (reference sequence NM_001171.5, MLPA kit P092B 
((https://www.mrcholland.com/)). The pathogenicity of all ABCC6 
variants was estimated based on the Sherloc criteria, a refinement of the 
guidelines for variant classification of the American College of Medical 
Genetics and Genomics –Association for Molecular Pathology, and 
classified as benign (class 1), likely benign (class 2), variant of unknown 
significance (VUS, class 3), likely pathogenic (class 4) or pathogenic 
(class 5) [20,21]. Patients with benign and likely benign variants were 
excluded from the analysis. VUS with a tendency towards benign or 
pathogenic, as based on the Sherloc criteria, were classified as such. 
Variants were classified into three groups [1]: truncating variants 
(nonsense, out-of-frame insertions or deletions, splice site variants that 
result in a frameshift, and deletions of the whole ABCC6 gene) [2], 
non-truncating variants with presumably some residual conservation of 
the protein function (missense variants, in-frame insertions or deletions 
and splice site variants that result in the lack of an in-frame exon) and 
[3] variants in which the effect is not clear. The third group was 
excluded from all analyses. Patients were grouped as having two trun-
cating variants, a mixed genotype of one truncating and one 
non-truncating variant, or two non-truncating variants. 
2.3. Arterial phenotypes 
2.3.1. Arterial calcification 
Arterial calcification mass was measured on unenhanced low dose 
(<3 mSv for a 70 kg adult), whole body CT multi-detector row CT 
scanners (Siemens or Philips, mAs dependent on body weight, 100 or 
120 kVp, slice thickness <1 mm which were resampled to 5 mm slices 
with 4 mm increment) in the carotid siphon, common carotid artery, 
coronary arteries, thoracic and abdominal aorta, iliac arteries and the 
femoral and crural arteries. A peripheral artery score was calculated as 
the sum of the calcification mass scores in the femoral and crural arteries 
and a total arterial calcification mass score was calculated as the sum of 
the mass scores in all different arterial beds. Arterial calcification was 
defined as hyperdense arterial wall lesions with a density above 130 
Hounsfield Units (HU). Calcification mass scores were computed as the 
product of the volume of the lesion in ml and the mean attenuation in 
HU. 
2.3.2. Ankle-brachial index 
The ankle-brachial index (ABI) after treadmill test was used to 
measure PAD. To calculate the ABI, the systolic blood pressure was 
measured in the left and right brachial arteries, the tibial posterior ar-
teries and the dorsal pedal arteries. During the treadmill test, patients 
were encouraged to walk on a treadmill with a 10% slope and a speed of 
3.5 km/h for 6 min. Patients who stopped prematurely due to pain 
(claudication) were encouraged to continue walking as soon as possible. 
During recovery, the ABI was measured during 10 min in a supine po-
sition. The lowest value of these ABI measurements was used as the post- 
treadmill test ABI. ABI measurements were performed by experienced 
technicians. PAD was defined as an ABI<0.90. 
2.4. Skin phenotype 
The presence of pseudoxanthomas was systematically scored by the 
treating physician in the neck (posterior, lateral, anterior), lower lip, 
axillas, elbows, umbilicus, and groins. The total number of locations was 
used as a measure of the extent of the skin involvement. 
2.5. Ophthalmological phenotypes 
All patients underwent routine ophthalmological examination, 
including best-corrected visual acuity (BCVA) and indirect ophthal-
moscopy. Imaging included macular spectral domain optical coherence 
tomography (SD-OCT), fundus autofluorescence (FAF), near-infrared 
reflectance imaging (NIR) (all Spectralis HRA-OCT, Heidelberg 
J.W. Bartstra et al.                                                                                                                                                                                                                             
Atherosclerosis 324 (2021) 18–26
20
Engineering, Heidelberg, Germany) and color fundus photography (FF 
450 plus, Carl Zeiss Meditec AG, Jena, Germany). For this study, the 
ophthalmological data of the first visit was used. 
2.5.1. Length of angioid streaks 
Since angioid streaks are assumed to occur in an already calcified 
area of Bruch’s membrane, the length of angioid streaks on 55◦ NIR 
imaging was used as a proxy for the extent of Bruch’s membrane 
calcification. The length of the longest angioid streak from the center of 
the optic disc to the retinal periphery was measured and graded into four 
zones: zone 1 (<3 mm from the center of the optic disc), zone 2 (3–6 
mm), zone 3 (6–9 mm) and zone 4 (>9 mm) (Supplemental Fig. 1). We 
used five 55◦ NIR images of the posterior pole and mid-periphery for the 
grading, and color fundus photography was used for comparison when 
in doubt. In eyes with extensive macular pathology, grading of angioid 
streaks was not possible and these were graded as ‘not assessable’ and 
excluded from the analysis. 
2.5.2. Macular phenotype 
The presence of choroidal neovascularizations and the severity of 
macular atrophy were scored in both eyes by three experienced graders 
(SR, RvL, JOvN). The presence of (in)active choroidal neo-
vascularizations was based on assessment of SD-OCT, fundus photog-
raphy and fluorescein- or indocyanine green angiography, if available. 
The presence of macular atrophy was based on FAF, SD-OCT, color 
fundus photography and NIR. The largest area of macular atrophy was 
graded as ‘no atrophy’, ‘mild atrophy’ (<twice the area of the optic disc) 
or ‘severe atrophy’ (>twice the area of the optic disc). An atrophic zone 
<0.5 optic disc diameter surrounding an (in)active choroidal 
neovascularizations was considered to be caused by the choroidal neo-
vascularizations and therefore not classified as macular atrophy. Before 
2018, both Snellen charts and Early Treatment of Diabetic Retinopathy 
Study (ETDRS) charts were used. From 2018 on, only ETDRS charts were 
used. BCVA was converted to the logarithm of the minimum angle of 
resolution (logMAR). 
2.6. Statistical analysis 
Patient characteristics are presented as mean ± standard deviation 
for normally distributed continuous variables, median (interquartile 
range (IQR)) for non-parametric distributed continuous variables and 
number (%) for categorical variables. For the ophthalmological pheno-
types, data of the right eye was used for descriptive and regression an-
alyses, and for the latter the left eye was used as a confirmation. If 
imaging of the right eye was not assessable, the left eye was used. 
Regression models were built with genotype as the determinant and 
calcification and clinical phenotypes as the outcome for all clinically 
proven PXE patients. Log10 transformation was performed on the 
calcification mass scores. Linear regression models were built for 
continuous outcomes (calcification mass scores, ABI, BCVA), logistic 
regression models were used for binary outcomes (the presence of 
choroidal neovascularizations), ordinal logistic regression models were 
built for ordinal outcomes (extent of angioid streaks, severity of macular 
atrophy) and Poisson regression models were built for count data 
(number of locations of pseudoxanthomas). All models were adjusted for 
age and sex. The models including arterial calcification mass were 
additionally adjusted for scanner vendor and differences in settings, 
since this affects calcification mass scores [22]. As a sensitivity analysis, 
Table 1 
Patient characteristics.   
All clinically confirmed PXE patients 
Two truncating variants1 Mixed genotype2 Two non-truncating variants3 p1 vs.2 p1 vs.3 
Total, n 158 96 18   
Age 51 [40-60] 54 [41 -61] 47 [44-54] 0.58 0.46 
Male sex 55 (35) 36 (38) 5 (28) 0.67 0.54 
Vascular, n 148 92 18   
Peripheral arterial calcification 
Prevalence 130 (88) 70 (76) 14 (78) 0.02 0.24 
Mass score 601 [46-2144] 246 [2-1844] 196 [4-553] 0.11 0.06 
Total body arterial calcification 
Prevalence 143 (97) 85 (92) 18 (100) 0.14 0.43 
Mass score 1944 [204-59836] 1118 [46-4291] 280 [53-2836] 0.21 0.18 
Ankle brachial index 0.90 [0.60–1.03] 0.98 [0.70–1.06] 0.89 [0.69–1.06] 0.07 0.76 
Peripheral arterial disease 77 (50) 39 (41) 9 (50) 0.16 0.98 
Pseudoxanthomas, n 154 91 18   
Prevalence 137 (89) 82 (90) 17 (94) 0.78 0.47 
Number of locations 4 [2-5] 3 [2-5] 3 [2-5] 0.94 0.68 
Ophthalmology, n 156 96 18   
Extent of angioid streaks 
Missing 6 5 1   
<3 mm 2 (1) 1 (1) 0 (0) 0.10 0.50 
3–6 mm 30 (20) 31 (34) 6 (35)   
6–9 mm 49 (33) 22 (24) 4 (24)   
>9 mm 69 (46) 37 (41) 7 (41)   
choroidal neovascularizations, prevalence 96 (62) 50 (52) 8 (44) 0.14 0.16 
Atrophy 
Mild 18 (12) 14 (15) 2 (11) 0.75 0.22 
Severe 22 (14) 12 (13) 0 (0)   
Visual acuity, logMAR 0.10 [0.00–0.80] 0.08 [–0.02–0.56] 0.03 [–0.07–0.37] 0.59 0.21 
Data is presented as median [IQR] or n (%). Data was analyzed with the Mann-Whitney U test or the χ2 test when appropriate. A p-value <0.05 was regarded as 
statistically significant. LogMAR = Logarithm of the minimum angle of resolution, PAD was defined as an ankle brachial index <0.90. 
Data are presented for the right eye, unless imaging could not be assessed, then the left eye was used. The extent of the angioid streaks was measured as the extent of the 
longest angioid streak from the center of the optic disk on 55◦ near infrared reflectance (NIR) imaging. One patient did not have 55◦ NIR imaging, and in 11 patients, 
severe scarring or atrophy impaired reliable gradin 
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Fig. 1. Correlation between genotypes and different vascular, skin and ophthalmological phenotypes in all clinically confirmed PXE patients. 
Patients with two truncating variants have higher arterial calcification mass, lower ankle brachial index, longer angioid streaks and higher prevalence of choroidal 
neovascularizations than patients with a mixed genotype. 
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Fig. 2. PXE is a slowly progressive disease. 
Except for the number of locations with pseudoxanthomas on the skin, the severity of all phenotypes increases with age in both patients with two truncating variants 
(red) and patients with a mixed genotype (blue). Data on patients with two non-truncating variants was not shown, since patient numbers were too low to show per 
decade. For eye data, details of the right eye are shown. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of 
this article.) 
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additional models excluding patients with a VUS were built. The length 
of angioid streaks mainly varies in patients younger than 50 years and 
appears static in patients older than 50 years [23]. Therefore, we per-
formed a subgroup analysis in patients younger than 50 years for the 
length of angioid streaks. Additional models were built excluding pa-
tients with two non-truncating variants since this group had very low 
patient numbers. A p-value <0.05 was regarded statistically significant. 
All analyses were performed in R studio version 1.1.456. The additional 
package ‘ordinal’ (version 2019.12–10) was used to build ordinal lo-
gistic regression models. 
3. Results 
3.1. Participants 
In total, 289 clinically confirmed PXE patients were included from 
243 families. Genotyping was performed in 282 patients (97%), 273 
patients (95%) had a CT scan, 283 patients (98%) had ABI measure-
ments, in 278 patients (96%) the pseudoxanthomas were scored, and 
287 patients (99%) had retinal imaging. Of all clinically confirmed PXE 
patients, 158 (55%) had two truncating variants, 96 (33%) had a mixed 
genotype, 18 (6%) had two non-truncating variants, 1 (0.3%) had a 
variant of which the effect was not clear, in 6 patients (2%) only one 
pathogenic variant was found, and in 2 patients (0.7%) no pathogenic 
variants were found. One patient (0.3%) had, besides two ABCC6 vari-
ants, a VUS in the ENPP1 gene, and was therefore excluded from the 
analyses. In 50 of the 67 homozygous patients (76%), the deletion of the 
same exon was excluded with MLPA. For the other 17 patients, this data 
was not available. For an overview of the classification, pathogenicity 
and frequency of individual variants, see Supplementary Table 1. 
3.2. Patient characteristics 
The median age at genetic analysis was 51 [IQR, 41-60] years in 
patients with two truncating variants, 54 [IQR, 41 -61] years (p = 0.58 
vs. two truncating variants) in patients with a mixed genotype, and 47 
[44-54] years (p = 0.46) in patients with two non-truncating variants. 
PXE patients with two truncating variants had more often peripheral 
arterial calcification (88% vs. 76%, p = 0.01) than patients with a mixed 
genotype. Although not statistically significant, higher peripheral 
arterial calcification mass score (601 [46-2144] vs. 246 [2-11844], p =
0.11), lower ABI (0.90 [0.60–1.03] vs. 0.98 [0.69–1.06], p = 0.07) and a 
higher prevalence of choroidal neovascularizations (96 (62%) vs. 50 
(52%), p = 0.10) were found in patients with two truncating variants. 
The prevalence and number of locations of pseudoxanthomas did not 
differ between the groups of patients (Table 1). Fig. 1 shows the phe-
notypes stratified for genotypes. Since PXE is a slowly progressive dis-
ease, we also looked at the correlation between phenotype and genotype 
per decade (Fig. 2). A subgroup analysis excluding patients with a VUS 
and a subgroup analysis in patients younger than 50 years showed that 
patients with two truncating variants have longer angioid streaks than 
patients with a mixed genotype (p = 0.02 and p = 0.04, respectively) 
(Supplementary Table 2 and Supplementary Fig. 2). Characteristics of 
patients with variants in which the effect is not clear and patients with 
only one or no variants are presented in Supplementary Table 3. 
3.3. Genotype-phenotype association 
When adjusted for age and sex, there was a significant association 
between the genotype (two truncating variants, mixed genotype, two 
non-truncating variants) and peripheral and total arterial calcification 
mass score (β: -0.25, 95%CI [-0.43; − 0.08] and − 0.14 [-0.28; − 0.00] 
respectively) and prevalence of choroidal neovascularizations (OR: 
0.55, 95% CI [0.31; 0.92]), although these associations attenuated after 
exclusion of patients with a VUS (Table 2). In younger PXE patients 
below 50, the genotype was associated with shorter angioid streaks 
(pOR 0.54, 95%CI [0.30; 0.95]). This association attenuated after 
exclusion of patients with a VUS. Because of the low number of patients 
with two non-truncating variants (n = 18), this group was excluded from 
a subgroup analysis. When adjusted for age and sex, patients with a 
mixed genotype had significantly lower peripheral and total arterial 
calcification mass scores (β: -0.39, 95%CI: -0.62; − 0.17 and β: -0.28, 
95%CI: -0.47; − 0.10, respectively), shorter angioid streaks in patients 
below 50 (pOR: 0.34 [0.15; 0.78]) and a lower prevalence of choroidal 
neovascularizations (OR: 0.41 95%CI: 0.20; 0.83) compared to patients 
with two truncating variants. After exclusion of patients with a VUS, 
these results remained statistically significant for the peripheral and 
total arterial calcification mass scores and the angioid streaks in younger 
patients (Table 3). 
Table 2 
Genotype-phenotype correlation in pseudoxanthoma elasticum. When adjusted for age and sex, PXE patients with two truncating variants have higher arterial 
calcification mass scores and a higher prevalence of choroidal neovascularization. These association attenuated after exclusion of patients with a variant of unknown 
significance.  
Independent variable: two truncating variants, mixed genotype, two non-truncating variants. Two truncating variants was used as the reference. 
Phenotypes All clinically confirmed PXE patients Patients with variant of unknown significance excluded 
Age and sex adjusted model Age and sex adjusted model 
β/OR/RR [95%CI] β/OR/RR [95%CI] 
Vascular 
Peripheral calcification, mass score, βa − 0.25 [-0.43; − 0.08]* − 0.16 [-0.34; 0.02] 
Total body calcification, mass score, βa − 0.14 [-0.28; − 0.00]* − 0.10 [-0.25; 0.06] 
Ankle brachial index, βa 0.03 [-0.02; 0.08] 0.01 [-0.04; 0.07] 
Skin 
Pseudoxanthomas, number of locations, RRb 0.99 [0.88; 1.10] 1.01 [0.90; 1.13] 
Ophthalmology 
Angioid streaks, extending zones, pORc 0.73 [0.50; 1.07] 0.86 [0.56; 1.32] 
Angioid streaks, extending zones, pORc, younger patients 0.54 [0.30; 0.95]* 0.60 [0.31; 1.11] 
Choroidal neovascularizations, presence, ORd 0.55 [0.32; 0.92]* 0.64 [0.36; 1.11] 
Atrophy, severity, pORc 0.76 [0.45; 1.26] 0.86 [0.49; 1.47] 
Visual acuity, βa − 0.08 [-0.19; 0.03] − 0.04 [-0.16; 0.08] 
Regression models were built with genotype as the determinant and the different phenotypes as the outcome. 
a Linear regression model (β). 
b Poisson regression model (rate ratio (RR). 
c Ordinal regression model (proportional odds ratio (pOR). 
d logistic regression model (OR). *p-value <0.05. 
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4. Discussion 
Here we show that PXE patients with a mixed genotype have less 
severe arterial calcification compared to patients with two truncating 
variants in the ABCC6 gene. Especially in PXE patients younger than 50 
years, the mixed genotype was associated with shorter angioid streaks as 
a measure of Bruch’s membrane calcification. Although a trend towards 
lower prevalence of choroidal neovascularizations was seen, we could 
not confirm an association between the genotype and skin involvement, 
peripheral arterial disease, choroidal neovascularizations, macular at-
rophy or visual acuity in our most stringent analyses. Research into 
other factors, including environmental risk factors and genetic modifiers 
might provide further insights into the unexplained phenotypic vari-
ability and might further improve risk classification in PXE. 
A previous study showed that patients with two loss-of-function 
variants had an increased risk of severe claudication and vascular sur-
gery, and subretinal hemorrhage as measured with the Phenodex clas-
sification [11]. Most genotype-phenotype correlation studies in PXE, 
however, did not find a correlation between the genotype and derma-
tological, arterial or ophthalmological phenotype [10,12,24–26]. Be-
sides the large heterogeneity in clinical phenotypes [10,12], these 
studies are typically hindered by lower patient numbers (15-134 pa-
tients) due to the rarity of the disease [10,12,24–26]. Even though we 
included a fairly sized cohort for this disease, we still had borderline 
statistical power and larger studies might be warranted. Most studies 
have looked into the correlation between the genotype and clinical 
outcomes based on the Phenodex classification [12]. This classification 
includes clinical outcomes in all affected organs in PXE, but does not 
include direct (semi)quantitative measures of ectopic calcification. 
Since calcification in the vasculature and Bruch’s membrane underlies 
and probably precedes the clinical consequences of PXE, measures of 
calcification might provide a better intermediate measure for 
genotype-phenotype correlation studies and might help with the initial 
staging of the severity of the disease in these organs. 
Approximately 50% of PXE patients in our cohort had PAD, as 
defined by an ABI below 0.9, which is in line with a previous study [3]. 
Although the prevalence of PAD was slightly higher in PXE patients with 
two truncating variants compared to patients with a mixed genotype, 
this difference was not statistically significant. Previous studies showed 
that the presence and extent of femoral artery calcification correlates 
with peripheral arterial disease in PXE [27]. The clear association be-
tween genotype and arterial calcification mass in our study suggests that 
patients with a more severe genotype might suffer from more severe 
PAD. Larger studies into the correlation between arterial calcification 
mass and peripheral arterial disease in PXE are awaited. 
Since angioid streaks are limited to the area of Bruch’s membrane 
calcification, we used the length of angioid streaks as a proxy for the 
extent of calcification in Bruch’s membrane of the retina. Especially in 
PXE patients younger than 50 years, two truncating variants increased 
the risk of longer angioid streaks compared with a mixed genotype. 
Eventually, choroidal neovascularizations will develop in nearly all PXE 
patients [28] but they tend to develop earlier in patients with two 
truncating variants (Fig. 2). Since longer streaks were recently shown to 
increase the risk for choroidal neovascularizations and macular atrophy, 
the increased length of angioid streaks at a younger age might underlie 
the possible association between the genotype and choroidal neo-
vascularizations that we found. Since Bruch’s membrane calcification 
impedes the diffusion of oxygen and nutrients to the outer retina and has 
an effect on the vitality of the outer retina at a young age, macular at-
rophy could be considered as the natural endpoint of Bruch’s membrane 
calcification. Macular atrophy might therefore serve as a better clinical 
endpoint to study Bruch’s membrane calcification in PXE [29]. In this 
study, however, we did not find an increased risk of macular atrophy for 
more severe genotypes. Probably, environmental risk factors, such as 
smoking, or genetic modifiers, such as variants of the VEGF-A gene are 
involved in the variability in the ophthalmological phenotype as well 
[26]. 
Currently, over 300 different variants in the ABCC6 gene have been 
described. The most common variants in our cohort were the truncating 
p.(Arg1141*) variant, the p.(Trp1259Glyfs*14) and p.(Lys1394Asnfs*9) 
frameshift variants and the exon 23-29 deletion, which corresponds with 
previous publications on ABCC6 variants in PXE [10–12]. However, 51 
of the 86 individual variants in our cohort were missense variants. Most 
of these variants have a low population frequency, or are unique for 
different families and 19 of these 51 missense variants were classified as 
a VUS [20]. Since all PXE patients had a confirmed clinical diagnosis, we 
included patients with a VUS in our primary analysis. Subgroup analysis 
excluding those patients with a VUS yielded similar point estimates but 
Table 3 
Genotype-phenotype correlation in pseudoxanthoma elasticum in patients with two truncating variants and a mixed genotype. When adjusted for age and sex, PXE 
patients with two truncating variants have higher arterial calcification mass, longer angioid streaks and a higher prevalence of choroidal neovascularization. After 
exclusion of patients with a variant of unknown significance, these associations remained significant for the arterial calcification mass scores and the length of angioid 
streaks in patients below 50 years old.  
Independent variable: two truncating variants and mixed genotype. Two truncating variants was used as the reference. 
Phenotypes All clinically confirmed PXE patients Patients with variant of unknown significance excluded 
Age and sex adjusted model Age and sex adjusted model 
β/OR/RR [95%CI] β/OR/RR [95%CI] 
Vascular 
Peripheral calcification, mass score, βa − 0.39 [-0.62; − 0.17]* − 0.33 [-0.57; − 0.09]* 
Total body calcification, mass score, βa − 0.28 [-0.47; − 0.10]* − 0.25 [-0.46; − 0.05]* 
Ankle brachial index, β a 0.06 [-0.01; 0.12] 0.03 [-0.04; 0.11] 
Skin 
Pseudoxanthomas, number of locations, RRb 1.01 [0.88; 1.17] 1.09 [0.94; 1.26] 
Ophthalmology 
Angioid streaks, extending zones, pORc 0.62 [0.37; 1.02] 0.74 [0.43; 1.30] 
Angioid streaks, extending zones, pORc, younger patients 0.34 [0.15; 0.78]* 0.36 [0.15; 0.83]* 
Choroidal neovascularizations, presence, ORd 0.41 [0.20; 0.83]* 0.50 [0.23; 1.07] 
Atrophy, severity, pORc 0.87 [0.46; 1.64] 1.02 [0.50; 2.03] 
Visual acuity, β a − 0.07 [-022; 0.07] 0.05 [-0.11; 0.22] 
Regression models were built with genotype as the determinant and the different phenotypes as the outcome. 
a Linear regression model (β). 
b Poisson regression model (rate ratio (RR). 
c Ordinal regression model (proportional odds ratio (pOR). 
d Logistic regression model (OR). * p-value <0.05. 
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resulted in wider confidence intervals and loss of statistical power. Since 
different missense variants result in proteins with differing residual 
transporter function or proteins that are retained intracellularly, such 
variants might still result in a non-functional protein [16]. Variants in 
arginine are frequent missense variants in our cohort. In general, argi-
nine is important for the protein structure. These variants might there-
fore have different consequences than others, although we do not see 
this in our cohort (data not shown). Additional functional analysis of 
missense variants in the ABCC6 gene could provide further insight into 
the unexplained phenotypic variability. The precise function of ABCC6 
is still not clear, but it has been shown that PXE patients have lower 
systemic levels of PPi [6,9,30]. PPi is an important inhibitor of calcifi-
cation and the low levels seen in PXE likely play a role in the high 
calcification propensity in PXE. PPi might therefore be an important 
biomarker for the severity or predict the progression of PXE. Intraperi-
toneal PPi supplementation halted calcification in mice and oral PPi 
increased plasma PPi levels in healthy volunteers [9,31]. In addition, 
several other therapies that interfere in the PPi homeostasis or ectopic 
calcification are being developed for PXE and related disorders [32]. 
Currently, no data on the association between the different genotypes 
and plasma PPi levels, or the association between plasma PPi and 
calcification and clinical consequences are available. 
A strength of this study is the large amount of multidisciplinary data 
we collected in a relatively large number of PXE patients. Several limi-
tations of this study have to be addressed. Due to the small number of 
patients with two non-truncating variants, no conclusions can be drawn 
for this group. However, since arterial calcification and the prevalence 
of choroidal neovascularizations in this group was comparable to the 
group with a mixed genotype, we expect that these patients have a 
milder phenotype than patients with two truncating variants. Quantifi-
cation of pseudoxanthomas based on the number of affected locations is 
a very rough estimate of the skin involvement in PXE. Currently, new in 
vivo methods to quantify elastin degradation, using two-photon micro-
scopy [33], or calcification of the skin using sodium fluoride PET/CT 
(NaF-PET/CT) are being developed [34]. Future research might want to 
look into the genotype-phenotype correlation based on these more so-
phisticated methods. Since we used data from regular clinical care, there 
is some heterogeneity in the CT scanner used (Siemens or Philips) and 
the settings of the scanner (100 or 120 kVp). These differences might 
have had an effect on the arterial calcification mass scores [22,35]. 
However, since we adjusted for CT vendor and settings in our regression 
models, we think it did not affect the findings of this study. The cate-
gorical classification of the length of angioid streaks leads to loss of 
information when compared to a continuous measure. Other ap-
proaches, including quantification of Bruch’s membrane reflectivity on 
macular OCT-scan [36] and measurement of the border of peau d’orange 
on 30◦ NIR imaging are under development. However, these measure-
ments are only possible in the early stage of disease when there is no 
macular degeneration yet [36,37]. The length of angioid streaks is the 
first measure that allows for semi-quantitative measurements in nearly 
all PXE patients, including those with end-stage disease. In 8 clinically 
confirmed PXE patients only one or no ABCC6 variants was found. Since 
MLPA currently only covers 23 of the 31 coding exons of the ABCC6 
gene, it might be that large deletions in the other eight exons were 
missed [38]. Since we excluded these patients from our 
genotype-phenotype analysis, this did not affect our results. Since we did 
not analyze the ENPP1 and GGCX gene in all patients, we cannot exclude 
the possibility that there are patients with variants in both ABCC6 and 
one of these genes, but since these are all rare diseases the chances are 
very low. Last, we did not perform segregation analyses in all patients. 
We therefore cannot prove that the pathogenic variants we found in 
heterozygous patients were indeed on different alleles. 
4.1. Conclusions 
In conclusion, we show that PXE patients with a mixed genotype 
have less severe arterial calcification and length of angioid streaks than 
PXE patients with two truncating variants in the ABCC6 gene. Research 
into the role of PPi, environmental risk factors or modifier genes might 
provide further insights into the unexplained phenotypic variability and 
improve risk classification in PXE. 
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